Journal article

The Genetics Company, Inc. - A newly founded Swiss Biotech Company

Morphogenetic pathways govern the processes that underlie embryonic development as well as self-renewal and homeostasis in adult tissues. The Genetics Company (TGC) exploits the untapped potential of morphogenetic pathways to develop new therapeutic approaches to human diseases with an initial focus on cancer and type-2 diabetes. TGC has established Morphogenetics(TM) as a proprietary strategy: To identify and validate novel modulators of tissue and organ development for new therapeutic applications, ranging from the morphogenetic remodeling of tumors to in vitro tissue engineering and organ regeneration To identify new drug targets through in vivo saturation mutagenesis in Drosophila To identify small compounds by means of an innovative in vivo screening technology in Drosophila (InvoScreen(TM)).


    Jenni, M. Genet Co Inc, Winterthurerstr 190, CH-8057 Zurich, Switzerland Genet Co Inc, CH-8057 Zurich, Switzerland Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland Swiss Inst Expt Canc Res, ISREC, CH-1066 Epalinges, Switzerland


    • UPAGU-ARTICLE-2000-001

    Record created on 2007-12-12, modified on 2016-08-08


  • There is no available fulltext. Please contact the lab or the authors.

Related material


EPFL authors